{"Symbol": "KIN", "AssetType": "Common Stock", "Name": "Kindred Biosciences, Inc", "Description": "Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Drug ManufacturersSpecialty & Generic", "Address": "1555 Bayshore Highway, Burlingame, CA, United States, 94010", "FullTimeEmployees": "156", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "164953600", "EBITDA": "-59615000", "PERatio": "None", "PEGRatio": "-0.16", "BookValue": "2.207", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-1.634", "RevenuePerShareTTM": "0.102", "ProfitMargin": "0", "OperatingMarginTTM": "-16.08", "ReturnOnAssetsTTM": "-0.3429", "ReturnOnEquityTTM": "-0.3046", "RevenueTTM": "3975000", "GrossProfitTTM": "3669000", "DilutedEPSTTM": "-0.765", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.299", "AnalystTargetPrice": "11.64", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "3.6858", "PriceToBookRatio": "1.8003", "EVToRevenue": "25.7851", "EVToEBITDA": "0", "Beta": "0.8978", "52WeekHigh": "11.24", "52WeekLow": "3.105", "50DayMovingAverage": "3.9172", "200DayMovingAverage": "5.1229", "SharesOutstanding": "39368400", "SharesFloat": "30315260", "SharesShort": "497971", "SharesShortPriorMonth": "479356", "ShortRatio": "2.34", "ShortPercentOutstanding": "0.02", "ShortPercentFloat": "0.0196", "PercentInsiders": "5.957", "PercentInstitutions": "67.656", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}